Description
Mazdutide is a next-generation anti-obesity and antidiabetic therapy currently in phase III clinical trials in China and under global investigation. It belongs to the incretin mimetic drug class, similar to tirzepatide (Mounjaro/Zepbound), but with a unique formulation and dosing strategy.
-
Drug Class: Dual GLP-1 and GIP receptor agonist
-
Developer: Eli Lilly (licensed to Innovent Biologics in China)
-
Administration: Subcutaneous injection (once weekly)
Mechanism of Action
Mazdutide works by mimicking two natural gut hormones:
-
GLP-1 Agonism
-
Slows gastric emptying
-
Reduces appetite and food intake
-
Enhances insulin secretion
-
Lowers glucagon levels
-
-
GIP Agonism
-
Enhances insulin release in a glucose-dependent manner
-
May improve fat metabolism and energy balance
-
Works synergistically with GLP-1 for greater weight loss and glycemic control
-
Clinical Benefits of Mazdutide (Based on Studies)
-
Significant weight loss – comparable or superior to semaglutide in early trials
-
Improved blood glucose control – lowers HbA1c levels in type 2 diabetes
-
Cardiometabolic improvements – reduction in cholesterol, triglycerides, and blood pressure
-
Potential NAFLD/NASH benefits – under investigation for fatty liver disease
-
Convenient dosing – once-weekly injection improves adherence.
Reviews
There are no reviews yet.